Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

6. Tobacco 133Green, D.E. (1980). Beliefs of teenagers about smoking and health. In R. M. Leauer &R. B. Shekelle (Eds.), Childhood prevention of atherosclerosis and hypertension (pp.223–228). New York: Raven Press.Hall, S. M., Tunstall, C., Rugg, D., Jones, R. T., & Benowitz, N. (1985). Nicotine gumand behavioral treatment in smoking cessation. J Consult Clin Psychol, 53, 256–258.Hansen, W. B. (1983). Behavioral predictors of abstinence: Early indicators of adependence on tobacco among adolescents. Int J Addict, 18, 913–920.Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzalez, D., Durcan, M. J., et al.(2001). Sustained-release bupropion for pharmacologic relapse prevention aftersmoking cessation: A randomized controlled trial. Ann Intern Med, 135, 423–433.Henningfield, J. E. (1986). How tobacco produces drug dependence. In J. K. Ockene(Ed.), The pharmacologic treatment of tobacco dependence: Proceedings of the WorldCongress (pp. 19–31). Cambridge, MA: Institute for the Study of Smoking Behaviorand Policy.Herrara, N., Franco, R., Herrara, L., Partidas, A., Rolando, R., & Fagerström, K. O.(1995). Nicotine gum, 2 and 4 mg, for nicotine dependence. Chest, 108, 447–451.Hughes, G.H., Hymowitz, N., Ockene, J. K., Simon, N., & Vogt, T. M. (1981). TheMultiple Risk Factor Intervention Trial (MRFIT): V. Intervention on smoking.Prev Med, 10, 476–500.Hughes, J. R., Gust, S. W., Keenan, R. M., Fenwick, J. W., & Healey, M. L. (1989).Nicotine vs placebo gum in general medical practice. JAMA, 261, 1300–1306.Hughes, J. R., Shiffman, S., Callas, P., & Zhang, J. (2003). A meta-analysis of the efficacyof over-the-counter nicotine replacement. Tob Control, 12, 21–27.Hunt, W. A., & Bespalec, D. A. (1974). An evaluation of current methods of modifyingsmoking behavior. J Clin Psychol, 30, 431–438.Hurt, R. D., Croghan, G., Beede, S., Wolter, T. D., Croghan, I. T., & Patten, C. A.(2000). Nicotine patch therapy in 101 adolescent smokers. Arch Pediatr AdolescMed, 154, 31–37.Hurt, R. D., Krook, J., Croghan, I., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., et al.(2003). Nicotine patch therapy based on smoking rate followed by bupropion forprevention of relapse to smoking. J Clin Oncol, 21, 914–920.Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., et al.(1997). A comparison of sustained-release bupropion and placebo for smoking cessation.N Engl J Med, 337, 1195–1202.Hurt, R. D., Wolter, T. D., Rigotti, N., Hays, J. T., Niaura, R., Durcan, M. J., et al.(2002). Bupropion for pharmacologic relapse prevention to smoking, predictors ofoutcome. Addict Behav, 27, 493–507.Hymowitz, N. (1987). Community and clinical trials of disease prevention: Effects oncigarette smoking. Public Health Rev, 15, 45–81.Hymowitz, N. (1999). Smoking cessation. In N. S. Cherniack, M. D. Altose, & I.Homma (Eds.), Rehabilitation of the patient with respiratory disease (pp. 319–353).New York: McGraw-Hill.Hymowitz, N., Corle, D., Royce, J., Hartwell, T., Corbett, K., Orlandi, M., & Piland, N.(1995). Smokers’ baseline characteristics in the COMMIT Trial. Prev Med, 24,503–508.Hymowitz, N., Cummings, K. M., Hyland, A., Lynn, W. R., Pechacek, T. F., & Hart-